As of July 2025, according to Edwards Lifesciences's latest financial report, the company's current EPS (TTM) is $7.03. Edwards Lifesciences's EPS for 2024 came in at $6.98, marking an increase from $2.31 in 2023. Edwards Lifesciences's earnings per share for the quarterly report ending on Mar 31, 2025 was $0.61.
The annual EPS in 2024 was $6.98, an increase of 202.2% from $2.31 in 2023. The quarterly EPS for the period ending Mar 31, 2025, was $0.61, marking a 5.2% increase from the same quarter last year. EW's TTM EPS stands at $7.03 as of March 2025. Edwards Lifesciences's EPS for 2023 stood at $2.31, a 6.1% decrease from 2022.
Edwards Lifesciences has recorded an increase in EPS of 5.2% over the last 12 months (YoY, quarterly). For the last three years, EW recorded an average annual EPS growth rate of 42.5%. Edwards Lifesciences had an average annual EPS growth rate of 33% over the last 5 years. Across the last decade, EW had an average annual EPS growth of 18.6%.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
EW Edwards Lifesciences Corp | 11.1 | 202.2% | 42.5% | 33% |
MDT Medtronic plc | 24.77 | 31% | -1.1% | 0.3% |
LMAT Lemaitre Vascular Inc | 41.43 | 44.1% | 15.6% | 16.6% |
MMSI Merit Medical Systems Inc | 44.73 | 26.2% | 34% | 83.3% |
BSX Boston Scientific Corp | 74.78 | 16.7% | 22.2% | -17.9% |
ICUI Icu Medical Inc | N/A | -292.7% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.